Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Jan 6, 2010

Premium

CrystalGenomics announced the appointment of Eric Nelson as its VP of business development. Headquartered in Seoul, Korea, CrystalGenomics operates a biopharmaceutical subsidiary in Emeryville, Calif., called CG Pharmaceuticals.

Previously, Nelson was the global head of business development at the Indian pharmaceutical firm Advinus Therapeutics. Before Advinus, Nelson was assistant VP of business development at Wyeth.


The Dr. Paul Janssen Award is accepting nominations until Feb. 15. The award, established by Johnson & Johnson and named after the Janssen Pharmaceutical founder, recognizes annually a scientist's contributions to public health through exemplary basic or clinical research advances with a $100,000 prize.

The award winner will be announced in the summer of 2010, according to a J&J statement.

Past winners of the Dr. Paul Janssen Award, include Axel Ullrich last year, and Marc Feldmann and Ravinder Maini in 2008.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.